Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05001087
Recruiting Observational

A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)

NCT05001087 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione EMN Italy Onlus
Phase
Observational
Started
2021-03-16
Last updated
2026-09-09

Condition(s) studied

Multiple Myeloma

Investigational drug(s) / intervention(s)

Observation

Observation: Not applicable-Observational study

Study summary

The aim of this observational study is the creation of a national multiple myeloma registry to monitor the current routine clinical practice in Italy and describe the standard of care adopted for the diagnosis and treatment of patients with multiple myeloma in the different Italian hematology centers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients of both sexes * Age ≥ 18 years * Diagnosis of active/symptomatic multiple myeloma (according to CRAB and biological parameters) no earlier than 1st January 2019 * Able and willing to sign an informed consent form Exclusion Criteria: * None considered

Primary outcome measure(s)

Trial sites (27)

FacilityCityRegionStatus
A.O.U di Careggi Florence Firenze Recruiting
AOU Ospedali Riuniti Umberto I Ancona Italy Recruiting
Policlinico di Bari - Ematologia con Trapianto Bari Italy Not Yet Recruiting
Policlinico di Bari Bari Italy Recruiting
Policlinico S. Orsola Bologna Italy Recruiting
A.O. Spedali Civili di Brescia Brescia Italy Recruiting
AOU Policlinico Vittorio Emanuele Catania Italy Recruiting
A.O.U Policlinico S. Martino Genova Italy Recruiting
ASST Santi Paolo e Carlo Milan Italy Recruiting
Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico Milan Italy Recruiting
Istituto Nazionale Tumori Milan Italy Recruiting
Ospedale Niguarda Cà Grande Milan Italy Recruiting
Ospedale San Gerardo di Monza Monza Italy Recruiting
A.O.U Federico II Naples Italy Not Yet Recruiting
Ospedale Maggiore Novara Italy Recruiting
A.O.U di Parma Parma Italy Recruiting
Policlinico San Matteo Fondazione IRCCS Pavia Italy Recruiting
Ospedale "Infermi" Rimini Italy Terminated
Ospedale S. Eugenio Roma Italy Recruiting
Policlinico Umberto I - Università La Sapienza Roma Italy Recruiting
Policlinico Universitario Campus Biomedico Roma Italy Recruiting
IRCCS Ospedale Casa Sollievo della Sofferenza San Giovanni Rotondo Italy Recruiting
A.O. Santa Maria Terni Italy Recruiting
A.O Ordine Mauriziano Torino Italy Recruiting
AOU Città della Salute e della Scienza di Torino Torino Italy Recruiting
Policlinico Universitario di Udine Udine Italy Recruiting
Ospedale di Circolo Varese Italy Recruiting

More Fondazione EMN Italy Onlus trials in Italy

Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study" Starting soon
A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients Active, not recruiting
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant Active, not recruiting

Other trials for the same condition

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Active, not recruiting
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) Active, not recruiting
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara Active, not recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Recruiting
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05001087 on ClinicalTrials.gov ↗ ← All trials in Italy